NCT00155376 is a Phase 4 clinical trial of morphine and glucagon in Liver Disease, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT00155376?

NCT00155376 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT00155376?

Interventions in NCT00155376: morphine and glucagon.

What condition does NCT00155376 study?

NCT00155376 studies Liver Disease.

Is NCT00155376 still recruiting?

NCT00155376 is currently status unknown. Last updated 25 November 2005.

Last reviewed 2005-11-25 · How we verify

NCT00155376

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography

Status unknown Phase 4 Last updated 25 November 2005

What this trial tests

Phase 4 trial testing morphine and glucagon in Liver Disease in 100 participants. Status unknown.

Timeline

1 September 2005

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	diagnostic
Enrollment	100
Start date	1 September 2005
Estimated completion	1 September 2005
Sites	1 location across Taiwan

Drugs / interventions tested

morphine and glucagon — full drug profile →

Conditions studied

Liver Disease — all drugs for Liver Disease →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 75, any sex, with Liver Disease. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

MRCP visibility

Sponsor's own description

Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Disease

Currently open trials in the same condition.

NCT04014413 — Safety and Efficacy of Fecal Microbiota Transplantation · NA · recruiting
NCT02382822 — Copenhagen Comorbidity in HIV Infection Study · active not recruiting
NCT00001971 — Evaluation of Patients With Liver Disease · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00155376 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 25 November 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00155376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing